Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Ex Vivo Mathematical Myeloma Advisor (EMMA) - a Clinical, Molecular, and Phenotypic Platform to Tailor Personalized Therapeutic Strategies for Multiple Myeloma

Rafael Renatino-Canevarolo, Maria Silva, Mark B Meads, Xiaohong Zhao, Alexandra Achille, David Noyes, Praneeth Reddy Sudalagunta, Raghunandan Reddy Alugubelli, Daniel Lastorino, Leticia Tordesillas, Miguel Gomez Fontela, Oliver Hampton, Daniel Abate-Daga, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2023) 142 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2023-190479

Published: 2023

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Ciara Louise L. Freeman, Xiaohong Zhao, Mark B Meads, Jerald Noble, Raghunandan Reddy Alugubelli, Rafael Renatino-Canevarolo, Oliver Hampton, Praneeth Reddy Sudalagunta, Ariosto Siqueira Silva, Rachid Baz, Melissa Alsina, Doris K. Hansen, Xiaofei Song, Kenneth H. Shain

Blood (2023) 142 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2023-191013

Published: 2023

Journal Articles

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Blood (2023) 142 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2023-185930

Published: 2023

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Praneeth Reddy Sudalagunta, Mark B. Meads, Rafael Renatino-Canevarolo, Maria L. Coelho Siqueira Silva, Xiaohong Zhao, Rhett Waldron, Christopher Cubitt, Raghunandan Reddy Alugubelli, Gabriel De Avila, Oliver Hampton, Robert Gatenby, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 4245–4246.

https://doi.org/10.1182/blood-2022-162454

Published: 2022

Journal Articles

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Rafael Renatino-Canevarolo, Mark B. Meads, Maria L. Coelho Siqueira Silva, Praneeth Reddy Sudalagunta, Christopher Cubitt, Gabriel De Avila, Raghunandan Reddy Alugubelli, Amit Kulkarni, Qi Zhang, Oliver Hampton, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 3036–3037.

https://doi.org/10.1182/blood-2022-163511

Published: 2022

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Rachid C. Baz, Jongphil Kim, Christine Sam, Brandon J. Blue, Sonila Toska, Aaron Collier, Jason Brayer, Ariel F Grajales-Cruz, Melissa Alsina, Ariosto Siqueira Silva, Kenneth H. Shain

Blood (2022) 140 (Supplement 1): 7313–7314.

https://doi.org/10.1182/blood-2022-159164

Published: 2022

Journal Articles

Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma

Ryan T Bishop, Tao Li, Raghunandan Reddy Alugubelli, Mark Meads, Bin Fang, Gabriel De Avila, Oliver Hampton, Steven Grant, John M. Koomen, Ariosto Siqueira Silva, Kenneth H. Shain, Conor Lynch

Blood (2022) 140 (Supplement 1): 5977–5978.

https://doi.org/10.1182/blood-2022-170103

Published: 2022

Journal Articles

Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma

Ryan T Bishop, Tao Li, Raghunandan R Alugubelli, Oliver Hampton, Ariosto Siqueira Silva, Steven Grant, Kenneth H. Shain, Conor C Lynch

Blood (2021) 138 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2021-152686

Published: 2021

Journal Articles

Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma

Nancy Gillis, Lauren C Peres, Christelle M Colin-Leitzinger, Mingxiang Teng, Raghunandan Reddy Alugubelli, Gabriel De Avila, Dongliang Du, Erin M Siegel, Jamie Teer, Oliver Hampton, Melissa Alsina, Jason Brayer, Brandon J. Blue, Ariosto Siqueira Silva, Rachid Baz, Taiga Nishihori, Kenneth H. Shain

Blood (2021) 138 (Supplement 1): 402.

https://doi.org/10.1182/blood-2021-147340

Published: 2021

Journal Articles

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Ariosto Siqueira Silva, PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria D Coelho Siqueira Silva, MSc, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Melissa Mitchell, Hongyue Dai, Qi Zhang, PhD, Oliver Hampton, Xin Lu, Dimple A. Modi, PhD, Monica Motwani, PhD, Jason Harb, PhD, Jeremy A. Ross, Kenneth H. Shain, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-134924

Published: 2020

Journal Articles

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Kenneth H. Shain, MD PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Constantine Logothetis, MD, Christian Argueta, PhD, Yosef Landesman, PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140485

Published: 2020

Journal Articles

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria Silva, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan R Alugubelli, MS, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142872

Published: 2020

Journal Articles

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Rupal Ramakrishnan, Alexandra Achille, Tuan Nyugen, Ian Taylor, BS, Gabriel De Avila, BS, Raghunandanreddy Alugubelli, MS, Mark B. Meads, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD

Blood (2019) 134 (Supplement_1): 4392.

https://doi.org/10.1182/blood-2019-131966

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

Journal Articles

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Kenneth H. Shain, MD PhD, Daniel Hart, Ariosto Siqueira Silva, PhD, Raghunandanreddy Alugubelli, MS, Gabriel De Avila, BS, Praneeth Reddy Sudalagunta, PhD, Alexandre Tungesvik, MD, Amit Kulkarni, PhD, Carmelo Blancuicett, PhD MD, Hongyue Dai, PhD, Taiga Nishihori, MD, Jason B. Brayer, PhDMD, Brandon Blue, MD, Melissa Alsina, MD, Rachid Baz, MD, William S. Dalton, PhDMD

Blood (2019) 134 (Supplement_1): 5511.

https://doi.org/10.1182/blood-2019-132234

Published: 2019

Journal Articles

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5534.

https://doi.org/10.1182/blood-2019-132001

Published: 2019

Journal Articles

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Anders Berglund, Paula S. Oliveira, Allison Distler, Praneeth Reddy Sudalagunta, PhD, Timothy Jacobson, Jamie Teer, PhD, Eric A. Welsh, PhD, Hongyue Dai, PhD, John M. Koomen, PhD, Alugubelli Raghunandan Reddy, Gabriel De Avila, Alexandre Tungesvik, MD, William Roush, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, John Cleveland, PhD

Blood (2019) 134 (Supplement_1): 5537.

https://doi.org/10.1182/blood-2019-130830

Published: 2019

Journal Articles

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2018-99-118004

Published: 2018

NARROW

Ex Vivo Mathematical Myeloma Advisor (EMMA) - a Clinical, Molecular, and Phenotypic Platform to Tailor Personalized Therapeutic Strategies for Multiple Myeloma

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma

Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma

Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Dynamic Epigenetic Landscapes Define Multiple Myeloma Progression and Drug Resistance

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only